The clinical pharmacology of antineoplastic agents (first of two parts).
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001215:Asparaginase / Q000494:pharmacology; D001665:Binding Sites; D001692:Biological Transport; D056486:Chemical and Drug Induced Liver Injury; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003864:Depression, Chemical; D004347:Drug Interactions; D004351:Drug Resistance; D005467:Floxuridine / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D005493:Folic Acid Antagonists; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008099:Liver / Q000378:metabolism; D008171:Lung Diseases / Q000139:chemically induced; D008727:Methotrexate / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D051379:Mice; D009369:Neoplasms / Q000378:metabolism; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D005493:Folic Acid Antagonists; D005467:Floxuridine; D013762:Tetrahydrofolate Dehydrogenase; D001215:Asparaginase; D005472:Fluorouracil; D008727:Methotrexate